What's a Drug Worth?

The transcript discusses the complexities of value-based contracts in the pharmaceutical industry, focusing on challenges like data collection, defining value, and pricing unique drugs. It highlights the role of independent bodies like ICER in determining drug value and explores policy suggestions to improve competition and pricing. The discussion also covers the international pricing index and its implications for the U.S. market, concluding with future prospects for outcome-based pricing and innovative treatments.

What new insight or understanding did you gain from this video?